Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [10]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 23997-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- AMPD3 antibody
- Antibody type
- Polyclonal
- Description
- AMPD3 antibody (Cat. #23997-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Self-amplifying nanomedicine reprograms redox metabolism to trigger immunogenic ferroptosis in colon cancer: multiomics identifies AMPD3 as a novel regulator.
Enhancer regulator MLL4 controls skeletal muscle metabolic efficiency by limiting AMPK-mediated fuel catabolism.
Morin Alleviates Fructose-Driven Disturbance of Podocyte Mitochondrial Energy Metabolism by Inhibiting Adenosine 5'-Monophosphate Deaminase Activity to Improve Glomerular Injury.
AMPD3 promotes doxorubicin-induced cardiomyopathy through HSP90α-mediated ferroptosis.
Role of AMP deaminase in diabetic cardiomyopathy.
Downregulation of extramitochondrial BCKDH and its uncoupling from AMP deaminase in type 2 diabetic OLETF rat hearts.
Discovery of Novel N-(5-(Pyridin-3-yl)-1H-indazol-3-yl)benzamide Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease.
Xanthine oxidoreductase-mediated injury is amplified by upregulated AMP deaminase in type 2 diabetic rat hearts under the condition of pressure overload.
Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease.
Translational regulation by miR-301b upregulates AMP deaminase in diabetic hearts.
Huang X, Wang L, Guan Q, Chen L, Qi H, Wang H, Qian Y, Song D, Hui Q, Yu H, Wei M, Zheng W, Li Z
Biomaterials 2026 Oct;333:124196
Biomaterials 2026 Oct;333:124196
Enhancer regulator MLL4 controls skeletal muscle metabolic efficiency by limiting AMPK-mediated fuel catabolism.
Yang L, Liu L, Wang W, Ding C, Asokan AK, Feng T, Zhou D, Xu Z, Fu T, Guo Q, Zhou Z, Pei S, Shen G, Xiao L, Yin Y, Sun Z, Mao Y, Sun W, Li J, Xue J, Zhu MS, Ge K, Sreekumaran Nair K, Piao HL, Gan Z
Nature communications 2025 Nov 26;16(1):11644
Nature communications 2025 Nov 26;16(1):11644
Morin Alleviates Fructose-Driven Disturbance of Podocyte Mitochondrial Energy Metabolism by Inhibiting Adenosine 5'-Monophosphate Deaminase Activity to Improve Glomerular Injury.
Yang Y, Wan Z, Huang L, Zhou Z, Wang W, Xing Y, Li S, Du Y, Huang J, Wu Y, Fan M, Li J, Kong L, Zhang D
Pharmaceuticals (Basel, Switzerland) 2025 Dec 12;18(12)
Pharmaceuticals (Basel, Switzerland) 2025 Dec 12;18(12)
AMPD3 promotes doxorubicin-induced cardiomyopathy through HSP90α-mediated ferroptosis.
Cheng L, Zhu M, Xu X, Li X, Yao Y, Liu C, He K
iScience 2024 Oct 18;27(10):111005
iScience 2024 Oct 18;27(10):111005
Role of AMP deaminase in diabetic cardiomyopathy.
Miura T, Kouzu H, Tanno M, Tatekoshi Y, Kuno A
Molecular and cellular biochemistry 2024 Dec;479(12):3195-3211
Molecular and cellular biochemistry 2024 Dec;479(12):3195-3211
Downregulation of extramitochondrial BCKDH and its uncoupling from AMP deaminase in type 2 diabetic OLETF rat hearts.
Ogawa T, Kouzu H, Osanami A, Tatekoshi Y, Sato T, Kuno A, Fujita Y, Ino S, Shimizu M, Toda Y, Ohwada W, Yano T, Tanno M, Miki T, Miura T
Physiological reports 2023 Feb;11(4):e15608
Physiological reports 2023 Feb;11(4):e15608
Discovery of Novel N-(5-(Pyridin-3-yl)-1H-indazol-3-yl)benzamide Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease.
Yang B, Zhang H, Li N, Gao L, Jiang H, Kan W, Yuan H, Li J, Zhao D, Xiong B, Zhou Y, Guo D, Liu T
Journal of medicinal chemistry 2022 Dec 8;65(23):15770-15788
Journal of medicinal chemistry 2022 Dec 8;65(23):15770-15788
Xanthine oxidoreductase-mediated injury is amplified by upregulated AMP deaminase in type 2 diabetic rat hearts under the condition of pressure overload.
Igaki Y, Tanno M, Sato T, Kouzu H, Ogawa T, Osanami A, Yano T, Kuno A, Miki T, Nakamura T, Miura T
Journal of molecular and cellular cardiology 2021 May;154:21-31
Journal of molecular and cellular cardiology 2021 May;154:21-31
Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease.
Mi Z, Song Y, Cao X, Lu Y, Liu Z, Zhu X, Geng M, Sun Y, Lan B, He C, Xiong H, Zhang L, Chen Y
Nature metabolism 2020 Aug;2(8):717-731
Nature metabolism 2020 Aug;2(8):717-731
Translational regulation by miR-301b upregulates AMP deaminase in diabetic hearts.
Tatekoshi Y, Tanno M, Kouzu H, Abe K, Miki T, Kuno A, Yano T, Ishikawa S, Ohwada W, Sato T, Niinuma T, Suzuki H, Miura T
Journal of molecular and cellular cardiology 2018 Jun;119:138-146
Journal of molecular and cellular cardiology 2018 Jun;119:138-146
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The AMPD3 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human AMPD3. This antibody recognizes human, mouse, rat antigen. The AMPD3 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
